Prognostic role of circulating cytokines and inflammation indexes for avelumab maintenance in metastatic urothelial carcinoma
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Identifying prognostic biomarkers for avelumab treatment in metastatic urothelial carcinoma (mUC) is crucial. Low systemic inflammation and specific cytokine profiles predict better response and survival in mUC patients receiving avelumab maintenance therapy.
Area Of Science
- Oncology
- Immunology
- Biomarker Discovery
Background
- Avelumab maintenance is a standard treatment for metastatic urothelial carcinoma (mUC).
- Prognostic biomarkers are needed to optimize treatment benefits and minimize toxicity.
- Circulating cytokines and inflammatory indexes are potential biomarkers for immune checkpoint inhibitors.
Purpose Of The Study
- To investigate the prognostic role of plasma cytokines and inflammation indexes in mUC patients receiving first-line avelumab maintenance.
- To correlate baseline biomarkers with clinical benefit, progression-free survival (PFS), and overall survival (OS).
- To assess the relationship between biomarkers and immune-related adverse events.
Main Methods
- Prospective collection of plasma cytokines and inflammation indexes in 28 mUC patients before avelumab treatment.
- Assessment of clinical benefit (CB) as the primary endpoint.
- Correlation analysis with PFS, OS, and immune-related adverse events as secondary endpoints.
Main Results
- High pre-treatment levels of interferon (IFN)-γ and interleukin (IL)-2 were associated with clinical benefit and longer survival.
- Low levels of IL-6, IL-8, neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), and systemic-inflammation index (SII) correlated with better outcomes.
- Low IL-8, NLR, and SII levels showed independent prognostic value for OS in multivariate analysis.
Conclusions
- Pre-treatment plasma cytokines and inflammation indexes may serve as prognostic biomarkers for avelumab efficacy in mUC.
- Patients with lower pre-therapeutic systemic inflammation and specific cytokine profiles demonstrated better response and survival.
- These biomarkers could aid in personalizing avelumab treatment strategies for mUC.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.